Neurocrine Biosciences (NBIX) Share-based Compensation Growth (1y) (2011 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.13 Bn | 625.38 Bn | 17.26 Bn | -119.48% |
| 2 | AbbVie | 442.39 Bn | 435.82 Bn | 12.70 Bn | -7.26% |
| 3 | Merck | 366.26 Bn | 359.12 Bn | 12.21 Bn | 37.96% |
| 4 | Novartis Ag | 266.58 Bn | 258.89 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.00 Bn | 147.30 Bn | 10.94 Bn | 22.66% |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 8 | Incyte | 25.41 Bn | 20.87 Bn | 1.57 Bn | 4.11% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | -49.74% |
| 10 | Neurocrine Biosciences | 15.59 Bn | 15.20 Bn | 935.80 Mn | 23.11% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.11% |
| Mar 31, 2026 | 8.33% |
| Dec 31, 2025 | -58.88% |
| Sep 30, 2025 | 29.40% |
| Jun 30, 2025 | 22.51% |
| Mar 31, 2025 | 18.65% |
| Dec 31, 2024 | 219.51% |
| Sep 30, 2024 | -13.18% |
| Jun 30, 2024 | -37.08% |
| Mar 31, 2024 | 11.53% |
| Dec 31, 2023 | 2.53% |
| Sep 30, 2023 | 10.90% |
| Jun 30, 2023 | 38.38% |
| Mar 31, 2023 | 7.84% |
| Dec 31, 2022 | 22.19% |
| Sep 30, 2022 | 16.17% |
| Jun 30, 2022 | 73.08% |
| Mar 31, 2022 | 12.46% |
| Dec 31, 2021 | 69.52% |
| Sep 30, 2021 | 38.95% |